Ascendis Pharma AS (ASND)vsRegeneron Pharmaceuticals Inc (REGN)
ASND
Ascendis Pharma AS
$210.45
-3.83%
HEALTHCARE · Cap: $13.32B
REGN
Regeneron Pharmaceuticals Inc
$635.45
+0.46%
HEALTHCARE · Cap: $63.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 1623% more annual revenue ($14.92B vs $865.78M). ASND leads profitability with a 57.3% profit margin vs 29.6%. REGN trades at a lower P/E of 14.7x. REGN earns a higher WallStSmart Score of 64/100 (C+).
ASND
Buy55
out of 100
Grade: C
REGN
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ASND.
Margin of Safety
+53.0%
Fair Value
$1350.89
Current Price
$635.45
$715.44 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 104 in profit
Keeps 57 of every $100 in revenue as profit
Revenue surging 144.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 30 of every $100 in revenue as profit
Attractively priced relative to earnings
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Elevated debt levels
Weak financial health signals
Trading at 23.3x book value
Weak financial health signals
Earnings declined 7.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : ASND
The strongest argument for ASND centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 57.3% and operating margin at 10.1%. Revenue growth of 144.3% demonstrates continued momentum.
Bull Case : REGN
The strongest argument for REGN centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 29.6% and operating margin at 20.7%. Revenue growth of 19.0% demonstrates continued momentum.
Bear Case : ASND
The primary concerns for ASND are EPS Growth, Debt/Equity, Piotroski F-Score. Debt-to-equity of 1.84 is elevated, increasing financial risk.
Bear Case : REGN
The primary concerns for REGN are Piotroski F-Score, EPS Growth.
Key Dynamics to Monitor
ASND carries more volatility with a beta of 0.48 — expect wider price swings.
ASND is growing revenue faster at 144.3% — sustainability is the question.
REGN generates stronger free cash flow (848M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (64/100 vs 55/100), backed by strong 29.6% margins and 19.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ascendis Pharma AS
HEALTHCARE · BIOTECHNOLOGY · USA
Ascendis Pharma A / S, a biopharmaceutical company, develops therapies for unmet medical needs. The company is headquartered in Hellerup, Denmark.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?